Piramal PharmaNSE:PPLPHARMA +1.10%60 Pretax Margin % is 1.56% as of Mar. 2026, which is 29% below its 10-year median of 2.21. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 60/100 and a GF Value™ of ₹174.09 (Fairly Valued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Piramal Pharma ranks worse than 69.35% on this metric.
The historical rank and industry rank for Piramal Pharma's Pretax Margin % or its related term are showing as below:
NSE:PPLPHARMA'
s Pretax Margin % Range Over the Past 10 Years
Min: -2.01 Med: 2.21 Max: 7.49
Current: -1.99
NSE:PPLPHARMA's Pretax Margin % is ranked worse than 69.35% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs NSE:PPLPHARMA: -1.99
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Piramal Pharma Pretax Margin % Related Terms
Piramal Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:PPLPHARMA vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a Pretax Margin % of 1.56% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Piramal Pharma and its competitors. This is 29% below median its historical median of 2.21. According to the industry distribution chart, Piramal Pharma ranks #663 out of 956 companies in the Drug Manufacturers industry, placing it in the top 69.4%.
Is Piramal Pharma's Pretax Margin % too high?
Piramal Pharma's current Pretax Margin % of 1.56% is 29% below median its 10-year median of 2.21. The Drug Manufacturers industry median Pretax Margin % is 7.29. Piramal Pharma's value of 1.56% is 78.6% below this industry median. Based on the distribution chart, Piramal Pharma ranks #663 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #663 out of 956 companies for Pretax Margin %. This places Piramal Pharma in the lower half of its industry. The industry median Pretax Margin % is 7.29. Piramal Pharma's value of 1.56% is 78.6% below this benchmark. While the company's 10-year median is 2.21 vs. the industry median of 7.29, Piramal Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current Pretax Margin % of 1.56% is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Pretax Margin % is 1.56%, which is 29% below median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹174.09, compared to a current price of ₹177.88 — trading 2.2% above its estimated fair value. The current Pretax Margin % is 1.56%, which is 29% below median its 10-year median of 2.21 and 78.6% below the Drug Manufacturers industry median of 7.29. Piramal Pharma's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Pretax Margin % is 1.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹177.88 is trading 2.2% above its estimated GF Value™ of ₹174.09.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
Pretax Margin %: 1.56% (29% below median its 10-year median of 2.21)
GF Value™: ₹174.09 vs. price of ₹177.88 (2.2% above fair value)
Industry Position: 78.6% below the Drug Manufacturers median (#663 of 956)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
60GF Score
Get the complete analysis for NSE:PPLPHARMA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
